Business Context and Reporting Period
Company: Castle Biosciences, Inc. (CSTL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A commercial-stage diagnostics company providing personalized, clinically actionable information for dermatologic cancers, Barrett's esophagus, uveal melanoma, and atopic dermatitis. The company operates a single reportable segment focused on the U.S. market.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $83,679 | $87,988 |
| Net Loss | $(14,522) | $(25,848) |
| Loss Per Share (Basic & Diluted) | $(0.49) | $(0.90) |
| Operating Loss | $(18,407) | $(27,928) |
| Gross Margin % | 72.8% | 49.2% |
| Cash and Cash Equivalents (End of Period) | $63,764 | $89,689 |
| Marketable Investment Securities | $197,921 | $182,776 |
| Total Debt (Net of Discount) | $10,066 | $10,057 |
| Net Cash Used in Operating Activities | $(22,129) | $(6,036) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 4.9% to $83.7 million. This was driven by a $21.9 million decrease in dermatologic revenues (primarily due to the loss of Medicare coverage for the DecisionDx-SCC test effective April 2025), partially offset by a $17.5 million increase in non-dermatologic revenues (driven by a 58% volume increase in TissueCypher tests).
- Improved Profitability: Net loss improved by 43.8% to $14.5 million. The operating loss narrowed by 34.1% primarily due to a $26.1 million reduction in amortization of acquired intangible assets. In Q1 2025, the company fully amortized the IDgenetix asset following its discontinuation; no such charge occurred in Q1 2026.
- Gross Margin Expansion: Gross margin percentage increased significantly from 49.2% to 72.8%, largely attributable to the absence of the accelerated amortization charge recorded in the prior year.
- Cash Flow Deterioration: Net cash used in operating activities increased to $22.1 million from $6.0 million. This was primarily due to higher operating expenditures and the timing of working capital changes, specifically $28.8 million in payments for annual bonuses and employee benefits (compared to $22.5 million in the prior year).
- Investment Activity: Net cash used in investing activities increased to $25.8 million, driven by higher purchases of property and equipment ($12.5 million vs. $4.7 million) and marketable securities.
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash, cash equivalents, and marketable securities ($261.7 million combined) are sufficient to fund operations for at least the next 12 months. The company expects expenses to increase as it expands its sales force, executes clinical studies, and develops new products.
- Product Launches: The company commenced a limited access launch of the AdvanceAD-Tx test for atopic dermatitis in November 2025, receiving approximately 650 orders in Q1 2026. It plans to expand availability throughout 2026.
- Reimbursement Risks:
- DecisionDx-SCC: Medicare coverage was discontinued in April 2025. The company has submitted reconsideration requests to Novitas and MolDX, which were confirmed as valid procedural steps, but no favorable outcome is guaranteed. Revenue from this test is expected to remain a smaller portion of results in 2026.
- General: Revenue recognition is heavily dependent on third-party payor reimbursement rates and coverage policies. Uncertainties in Medicare appeals and commercial payer contracts create variable consideration constraints.
- Legal Proceedings: The company is responding to a subpoena from the U.S. Department of Health and Human Services, Office of Inspector General, regarding billing practices and interactions with medical providers from 2015 to present. No claims have been made, and the company cannot estimate potential losses.
- Macroeconomic Risks: The company cites risks related to geopolitical conflicts (U.S./Iran, Ukraine/Russia), inflation, interest rate fluctuations, and potential supply chain disruptions.
Investor Verification Checklist
- Reimbursement Status: Verify the current status of the reconsideration requests for DecisionDx-SCC Medicare coverage and the potential impact on future dermatologic revenue.
- Cash Burn Rate: Assess the sustainability of the $22.1 million quarterly operating cash burn, particularly given the one-time nature of the bonus payments in Q1 2026.
- AdvanceAD-Tx Adoption: Monitor the transition of the AdvanceAD-Tx test from limited access to full commercial launch and its contribution to revenue growth.
- Debt Covenants: Review compliance with the 2024 Loan and Security Agreement, noting the interest-only period extension to December 2026 and the floating interest rate structure.
- Legal Exposure: Track developments regarding the HHS/OIG subpoena to determine if it results in material liabilities or reputational damage.